Test Price
2,800 AED✅ Home Collection Available
B4GAT1 Gene Muscular Dystrophy-Dystroglycanopathy Type A13 (MDDGA13) Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO Accredited Next-Generation Sequencing for full B4GAT1 gene coverage.
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance
Post-Test Tele-Consultation with Consultant Medical Genetics for result interpretation and family planning.
Insurance
Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The B4GAT1 gene test utilizes next-generation sequencing (NGS) to detect pathogenic mutations causing Muscular Dystrophy-Dystroglycanopathy Type A13 (MDDGA13), a severe congenital disorder characterized by brain malformations, eye anomalies, and profound hypotonia. Definitive molecular diagnosis guides clinical management, prognosis, and recurrence risk counseling for affected families in the UAE.
| Parameter | Our B4GAT1 NGS Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity (full gene coverage including all coding exons and splice sites) | Targeted mutation panel misses rare or novel variants |
| Methodology | Next-Generation Sequencing (NGS) of entire B4GAT1 coding region with deep intronic flanking coverage | Single-gene Sanger sequencing limited to known hotspots |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I emphasize that this B4GAT1 NGS test provides a definitive molecular anchor for diagnosing MDDGA13. However, results must always be interpreted alongside comprehensive neurological, ophthalmological, and developmental assessments. No single genetic finding replaces a holistic clinical evaluation. Our multidisciplinary team supports families through every stage—from pre-test counseling to post-result planning—ensuring each family fully understands the implications for their child and future pregnancies.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Clinical Advisory & Patient Safety Framework
Critical Pre-Test Requirements
Genetic counseling with a board-certified medical geneticist is mandatory before sample collection to confirm clinical indication, construct a three-generation pedigree, and obtain written informed consent as required under Federal Decree-Law No. 4 of 2016 on Medical Liability.
This test is confirmatory and prognostic, not intended for acute diagnostic triage. Any child presenting with new-onset seizures, respiratory distress, or signs of increased intracranial pressure requires immediate emergency medical attention independent of genetic testing.
Exclusion Criteria & Emergency Indicators
Exclusion Criteria
- Asymptomatic individuals without clinical suspicion or family history of MDDGA13; not intended for routine prenatal screening without prior genetic counseling.
- Patients with active bleeding disorders or inability to safely provide a blood or saliva-derived DNA sample.
Emergency Red Flags
- New-onset seizures, acute severe hypotonia (floppy infant), feeding intolerance, or respiratory compromise.
- Sudden visual loss, rapidly progressive microcephaly, or signs of elevated intracranial pressure.
- If any of these occur, seek emergency medical care immediately. The genetic test is confirmatory, not for acute management.
Patient FAQ & Clinical Guidance
1. What is the B4GAT1 gene test and who should consider it?
This NGS test identifies disease-causing mutations in the B4GAT1 gene responsible for congenital muscular dystrophy with brain and eye anomalies (MDDGA13). It is recommended for infants presenting with hypotonia, delayed motor milestones, structural brain defects such as cobblestone lissencephaly, and ocular malformations. The test is also offered to families with a known history of MDDGA13 for carrier testing and informed reproductive planning.
2. How is the sample collected and what are the requirements?
A standard peripheral whole blood sample is collected by our certified VIP Mobile Phlebotomy team at your home between 8 AM and 11 PM, adhering to ISO-certified cold-chain transport protocols. Alternatively, extracted DNA or a dried blood spot on an FTA card may be accepted. Pre-test genetic counseling is mandatory to document clinical history and obtain informed consent.
3. What do the results mean and how long does it take?
Results are available within 3–4 weeks. A positive report identifies a confirmed pathogenic variant in B4GAT1, establishing the diagnosis of MDDGA13 and enabling precise prognosis and recurrence risk counseling (autosomal recessive inheritance). A negative result or variant of uncertain significance (VUS) will be thoroughly discussed during a follow-up tele-consultation with our Consultant Medical Genetics to determine next steps, including possible additional testing.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Rights – Fully Protected Under UAE Law
All genetic testing and personal health information processed by DNA Labs UAE are strictly governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These laws mandate explicit patient consent, data minimization, purpose limitation, and secure storage. Clinical safety and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is never shared without your explicit written authorization.
DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | B4GAT1 Gene Sequencing – Muscular Dystrophy-Dystroglycanopathy Type A13 (MDDGA13) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (peripheral), Extracted DNA, or Dried Blood Spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) – full coding region & splice-site analysis |
| ICD-10-CM Code | G71.0 (Muscular Dystrophy) |
| LOINC Code | 83395-9 (Gene mutations found [Identifier] in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians